The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products.
Key takeaways are that:
EU and Member State authorities imposed multiple material antitrust...more
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active pharmaceutical ingredient (API)...more
10/23/2023
/ Cartels ,
Cephalon ,
Competition ,
Corporate Counsel ,
EU ,
European Commission ,
Generic Drugs ,
Life Sciences ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Teva Pharmaceuticals
On 14 July 2022, Advocate General (AG) Kokott delivered her much awaited (non-binding) Opinions in Cases C-176/19 P, Commission v Servier and Others and C-201/19 P, Servier and Others v Commission. ...more
On 14 June 2022, the Belgian Health Care Knowledge Centre (KCE), a think-tank funded by the Belgian government, published a report on the compulsory licensing of expensive medicinal products (the Report). ...more
In February 2022, the Belgian Competition Authority’s (the BCA) prosecution service (Auditoraat/Auditorat) adopted a settlement decision, sanctioning two pharmaceutical wholesalers, Pharma Belgium-Belmedis SA and Febelco CV,...more
The Belgian Chamber of Representatives recently approved a draft law transposing EU Directive 2019/1 to empower the competition authorities of the Member States to be more effective enforcers and to ensure the proper...more
The Court of Justice of the EU (ECJ) has for the first time ruled on the issue of settlement agreements involving a value transfer (monetary or otherwise) between the holder of a pharmaceutical patent and generic drug...more